Butenafine HCl 1% (BAY1896425)
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatitis, Phototoxic
Conditions
Dermatitis, Phototoxic
Trial Timeline
Jun 24, 2013 โ Jun 28, 2013
NCT ID
NCT04531527About Butenafine HCl 1% (BAY1896425)
Butenafine HCl 1% (BAY1896425) is a phase 3 stage product being developed by Bayer for Dermatitis, Phototoxic. The current trial status is completed. This product is registered under clinical trial identifier NCT04531527. Target conditions include Dermatitis, Phototoxic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04531540 | Phase 3 | Completed |
| NCT04531527 | Phase 3 | Completed |
Competing Products
20 competing products in Dermatitis, Phototoxic